glp-1 small molecule agonist A Small-Molecule Oral of the Human Glucagon-like Peptide-1 Receptor Innovative small molecule shows promise

Safety Profile Across clinical trials, Cerebrolysin appears generally safe for short-term use (up to 3 years studied)

The concept of biointelligence-inspired material platforms has further expanded the therapeutic paradigm

& Wenning, G

For peptide serums in particular, packaging can influence how well the active ingredients maintain their stability during storage and use

For example, the team led by Hai Wang has developed nanoscale mitochondrial inducers (mitoNIDs) that selectively eliminate mitochondria in tumor cells, reduce ROS levels in the TME, and restore the metabolic activity and function of CD8T cells [89]